Metabolism Disorder TRIZ Cases

Adult adipose stem cells differentiate into brown fat using specific growth media combinations.

Small molecule mediators block ApoCIII-driven CaV1 conductivity increases, preventing beta cell death while preserving normal insulin secretion dynamics.

Entacapone targets the FTO enzyme to lower serum LDL and triglycerides, addressing the lack of effective small molecule inhibitors for obesity.

Copolyamino acid excipients enhance basal insulin solubility in aqueous solutions.

Conjugating glucagon agonists with AMPK activators resolves the contradiction between lipid reduction and blood glucose elevation.

Combining GM-CSF with fosfomycin accelerates wound healing by promoting innate defense mechanisms.

Modified glucagon analog agonist compounds maintain biological performance while resolving poor solubility and stability trade-offs in aqueous buffers.

Oral curcumin administration reverses body wasting in cachexia subjects without adverse side effects.

Adherent stromal cells modulate the uteroplacental interface, reducing maternal morbidity and fetal mortality associated with severe preeclampsia.

An organic acid maintains magnesium solubility in the intestinal tract, overcoming pH-induced precipitation that limits absorption.

High-purity EPA ethyl ester reduces triglycerides without raising LDL-C, resolving statin therapy limitations.

Caseino-glycomacropeptide replaces free amino acids to mask unpleasant taste while maintaining complete nutrition for phenylketonuria patients.

Cyclic cell-penetrating peptides overcome the endosomal membrane barrier to deliver therapeutic agents directly into the cytoplasm.

A PEGylated exendin-4 analogue extends in vivo half-life through selective cysteine modification.

Segmented differentiation protocol yields glucose-responsive insulin-producing cells, resolving low efficiency in stem cell derivation.

Hybrid peptide activates GLP-1, GIP, and glucagon receptors to reduce side effects while maintaining therapeutic efficacy.

Novel PEG esters using 3,5-DC-2-HBSA activators acylate amino groups in pharmaceutical peptides and proteins while resolving hydrolytic instability issues.

Heating and fermenting polyphenol plant materials with specific lactic acid bacteria strains reduces post-meal insulin levels by 15-25%.

Engineered PAP mutants bind the HCV internal ribosome entry site to inhibit viral RNA translation while reducing cytotoxicity compared to standard treatments.

Halogenated insulin analogues use phenylalanine substitutions to enhance thermal stability, enabling refrigeration-free storage in resource-limited regions.

A germinated and fermented soybean extract rich in coumestrol targets climacteric symptoms through enhanced phytoestrogen activity.

Anti-PCSK9 antibodies lower LDL-C without skeletal muscle pain, resolving statin intolerance contradictions.

Cyclic polypeptide compounds bind specifically to human proprotein convertase subtilisin/kexin type 9 (PCSK9) to block receptor interaction.

Modified mRNA delivered by lipid nanoparticles restores deficient enzyme activity and reduces toxic metabolite accumulation in Fabry disease.

In vitro grape berry cell culture production yields high resveratrol quantities without the bitterness associated with traditional plant extraction methods.

Carboxylic acid derivatives with four cycles modulate the GLP-1 receptor to enhance glucose-stimulated insulin secretion.

Zinc and iron compounds precipitate insulin glargine at neutral pH, providing a stable 24-hour release profile that eliminates hypoglycemic spikes.

Administering recombinant leptin to non-lipodystrophic subjects increases serum leptin concentration and reduces hepatic lipid content.

Optimizing zinc ion concentration and pH preserves the pharmacokinetic profile of combined insulin and GLP-1 peptides while resolving physical stability issues.

Combining hTERT and Follistatin genes via AAV vectors extends telomeres and enhances muscle mass while minimizing carcinogenesis risks.

Segmented therapeutic compounds bind MAdCAM to confine immune suppression locally, reducing systemic infection risks while preserving organ acceptance.

Composite lipid emulsions provide critical DHA and ARA in small volumes, overcoming gastrointestinal immaturity and nutrient deficiencies in preterm infants.

Zinc complexes stabilize acylated insulin to prevent protamine-induced immunogenicity while ensuring consistent release.

A sugar-restricted high-fat diet reduces AST, ALT, and gamma-GTP levels in nonalcoholic fatty liver disease patients.

A lipid membrane substrate mimics stratum corneum intercellular lipids to evaluate skin roughening via myelin figure formation.

Tartaric acid forms diastereoisomeric salts with triazine derivatives to enable direct enantiomer separation.

A microneedle array with polyvinylpyrrolidone releases glucagon-like peptide analogues intradermally.

Maltose-negative yeast converts wort carbohydrates into non-alcoholic byproducts, resolving the trade-off between nutrient enrichment and alcohol accumulation.

A dual-analyte model measures free fatty acids alongside glucose to assess real insulin activity.

Sequential CD137 agonist followed by CTLA-4 blocker reduces immune-mediated colitis severity.

A liquid protein formulation uses polysorbate 80 and arginine to maintain high concentration stability.

Low molecular weight non-polymeric frameworks with multivalent affinity ligands form cross-linked materials that release insulin in response to glucose levels.

Isofagomine salts stabilize glucocerebrosidase enzyme activity by preventing aggregation and degradation during synthesis.

Non-aqueous vehicles protect peptides from DPP-IV metabolism while maintaining stability.

Fucose-linked insulin conjugates utilize endogenous lectins for proportional release, eliminating immune risks from exogenous multivalent molecules.

Gap junction modulators prevent pericyte loss and vascular leakage in early diabetic retinopathy.

A vanadium-coated orthopedic implant accelerates bone regeneration through localized insulin-mimetic delivery.